Airing weekdays at 7:30 A.M. on

Airing weekdays at 7:30 A.M. on

This episode of The Balancing Act takes you behind the scenes of a Broadway hit. Then, stay tuned as we go inside the pages of two leading publications, Porthole Cruise Magazine and First for Women.

First, we’re going behind the scenes with Come From Away, the remarkable true story of a small town in Canada that welcomed the world. Inspired by real-life events, the award-winning theatrical performance tells the story of 7,000 stranded airline passengers who nearly doubled the population of Gander, Newfoundland, in the days following September 11, 2001.

Cruise tourism is at a record high with more than 30 million passengers expected to sail the open waters this year. That’s why we’re sitting down with Bill Panoff, editor in chief of Porthole Cruise Magazine, to discuss all things cruises.

Then, Everest Funeral Concierge Services is back with another helpful tip – this time about cemetery rules and regulations.

You’ve probably seen First for Women at your local grocery store. In fact, it’s the second best-selling magazine at retail with 3.7 million active readers. Stay tuned as we sit down with First for Women’s Samantha Trenk, who’s sharing tips and tricks for women everywhere – including essential oils, teas, and more – as well as details on the first-ever Inspiring Joy Day.

Health, Wealth, Beauty, and Business

Bringing the best tips from the experts in Atlanta in business, beauty, wealth management, child healthcare, car shopping, and more. Each year, Atlanta’s Women’s Entrepreneurship Initiative selects 15 local female entrepreneurs for a 15-month business training program. We meet women who have grown their companies, created jobs, and broke through the glass ceiling. With some […]

iMCD is the deadliest subtype of Castleman disease. Approximately one third of patients die within five years of diagnosis, and another third die within 10 years if not treated.

There are no effective treatment options for people with unresectable or metastatic chondrosarcoma despite many attempts by multiple pharmaceutical companies over the past few decades.

Comments

comments